PO.PS01.03 · 人群科学
在黑人和西班牙裔乳腺癌幸存者中开展肠道微生物组研究的粪便样本采集可行性:一项初步研究
Feasibility of fecal sample collection for gut microbiome research among Black and Hispanic breast cancer survivors: A pilot study
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:肠道微生物组日益被认为是癌症发生、治疗反应和幸存期的促成因素。然而,很少有研究表征种族和族裔多样的乳腺癌(BC)幸存者的肠道微生物组。这项初步研究评估了在黑人和西班牙裔BC幸存者中开展微生物组研究的粪便样本采集可行性。
方法:我们邀请参加New Jersey Breast Cancer Survivors(NJBCS)研究的女性从2022年春季开始参与微生物组初步研究。NJBCS参与者通过NJ州癌症登记处识别,包括自我认定为黑人或西班牙裔的女性,经组织学确诊为BC,年龄20-75岁,能够讲和阅读英语或西班牙语,除非黑色素瘤皮肤癌外无既往癌症史。数据收集包括面对面的家庭访谈(BC诊断后约18-24个月),同意(以英语或西班牙语)参与微生物组初步研究的女性获得粪便样本自采集试剂盒。样本由参与者邮寄至Columbia Microbiome Core进行处理和储存。我们使用多变量logistic回归模型检验提供粪便样本的预测因素。候选预测因素包括社会人口学、生活方式和临床变量:诊断时年龄、诊断以来的时间、体重指数、种族和族裔、出生地、教育、婚姻状况、家庭年收入、保险状态、体力活动、吸烟、饮酒、肿瘤分期、癌症治疗、产次和合并症。我们使用后向剔除法以P < 0.10的统计显著性阈值选择变量。
结果:截至2025年7月,386名符合条件的女性中有358名(93%)参加了微生物组研究,292名提供了粪便样本(82%应答率),样本平均在诊断后20.4个月提供。黑人(81%)和西班牙裔(83%)参与者的应答率相似。样本在参与者采集后中位5天到达实验室。与提供粪便样本相关的因素包括家庭年收入和内分泌治疗。收入较高的女性参与可能性略低(≥$70,000对 < $25,000,比值比(OR):0.58;95%置信区间(CI):0.31, 1.07),而接受内分泌治疗(相对于未接受)的女性更可能提供样本(OR:1.97;95% CI:1.04, 3.71)。
结论与未来方向:这项初步研究证明了在黑人和西班牙裔BC幸存者中开展微生物组研究的粪便样本采集具有高可行性。这些发现支持开展更大规模研究以检验肠道微生物组组成是否促成BC预后和幸存期中的种族和族裔差异,并为减少差异的社区参与式微生物组研究奠定基础。
查看英文原文 English abstract
Background: The gut microbiome is increasingly recognized as a contributor to cancer development, treatment response, and survivorship. Yet few studies have characterized the gut microbiome among racially and ethnically diverse breast cancer (BC) survivors. This pilot study assessed the feasibility of fecal sample collection for microbiome research in Black and Hispanic BC survivors.
Methods: We invited women enrolled in the New Jersey Breast Cancer Survivors (NJBCS) study to participate in the microbiome pilot study beginning in Spring 2022. NJBCS participants, identified through the NJ State Cancer Registry, included self-identified Black or Hispanic women with histologically confirmed BC, aged 20-75 years, able to speak and read English or Spanish, with no previous history of cancer except non-melanoma skin cancer. Data collection included in-person home interviews (~18-24 months after BC diagnosis), and women who consented (in English or Spanish) to participate in the microbiome pilot were provided with fecal sample self-collection kits. Samples were mailed by participants to the Columbia Microbiome Core for processing and storage. We used multivariable logistic regression models to examine predictors of providing a fecal sample. Candidate predictors included sociodemographic, lifestyle, and clinical variables: age at diagnosis, time since diagnosis, body mass index, race and ethnicity, place of birth, education, marital status, annual household income, insurance status, physical activity, cigarette smoking, alcohol consumption, tumor stage, cancer treatment, parity, and comorbidities. We used backward elimination to select variables with a statistical significance threshold of P < 0.10.
Results: As of July 2025, 358 of 386 eligible women (93%) enrolled in the microbiome, and 292 provided fecal samples (82% response rate), with samples provided in a mean of 20.4 months since diagnosis. The response rate was similar for Black (81%) and Hispanic (83%) participants. Samples arrived at the core a median of 5 days after participant collection. Factors associated with providing a fecal sample included annual household income and endocrine therapy. Higher-income women were somewhat less likely to participate (≥$70,000 vs < $25,000 Odds Ratio (OR): 0.58; 95% Confidence interval (CI): 0.31, 1.07), while women who received endocrine therapy (compared to not) were more likely to provide a sample (OR: 1.97; 95% CI: 1.04, 3.71).
Conclusions and Future Directions: This pilot demonstrates high feasibility of fecal sample collection for microbiome research among Black and Hispanic BC survivors. These findings support the feasibility of larger studies to examine whether gut microbiome composition contributes to racial and ethnic differences in BC prognosis and survivorship and lay the groundwork for community-engaged microbiome research to reduce disparities.
利益披露 Disclosure
N. Zeinomar, None..
A. Kim, None..
S. Bjerklie, None..
T. Wang, None..
B. Qin, None..
E. V. Bandera, None.